BioVector® CHLA-15 人神经母细胞瘤细胞系 / BioVector® CHLA-15 Human Neuroblastoma Cell Line

通用定义 / General Definition:BioVector® CHLA-15 是一种源自人类神经母细胞瘤 (Neuroblastoma) 的细胞系。该细胞系建立于一名接受过强力联合化疗后的复发患儿的肿瘤组织。CHLA-15 在神经肿瘤研究中具有极高的临床代表性，因为它保留了治疗诱导的耐药特征。该细胞系最显著的分子特征包括 MYCN 基因扩增，这是神经母细胞瘤预后不良的关键遗传学标志。它常被用于研究肿瘤复发机制、耐药性演变以及开发针对 MYCN 扩增型肿瘤的新型靶向药物。

BioVector® CHLA-15 is a human cell line derived from Neuroblastoma. It was established from a tumor specimen obtained from a pediatric patient at the time of disease relapse following intensive multi-agent chemotherapy. CHLA-15 is highly clinically relevant as it retains features of therapy-induced resistance. A defining molecular hallmark of this line is the amplification of the MYCN oncogene, a critical prognostic factor for high-risk neuroblastoma. It is extensively utilized to investigate mechanisms of tumor recurrence, the evolution of drug resistance, and the development of novel targeted therapies for MYCN-amplified malignancies.

BioVector® CHLA-15 技术说明书 (Technical Datasheet)

中文版说明书 (Chinese Datasheet)

1. 产品基本信息

• 产品名称： BioVector® CHLA-15 人神经母细胞瘤细胞

• 组织来源： 腹后膜肿瘤（复发性神经母细胞瘤）

• 分子特征：MYCN 扩增；通常表现为对多种化疗药物（如烷化剂）的敏感性降低。

• 生长特性： 贴壁生长（细胞可能形成多层簇状结构）。

• 细胞形态： 上皮样及小圆细胞，胞浆较少，常可见神经突样延伸。

2. 培养条件

• 基础培养基： BioVector® IMDM 或 DMEM/F-12 (1:1)。

• 血清添加： 10% - 20% BioVector® 优质胎牛血清 (FBS)。

• 补充因子： 建议添加 1x ITS (胰岛素-转移蛋白-硒) 以支持细胞在低密度时的活力。

• 培养环境： 37 摄氏度，5% CO2。

• 传代比例： 1:2 至 1:4；细胞生长较缓慢且具有接触抑制减弱的特点。

3. 细胞应用

• 耐药机制研究： 对比初治细胞系，研究复发性肿瘤对顺铂、长春新碱等药物的耐药分子途径。

• MYCN 靶向研究： 利用该模型测试针对 MYCN 转录活性或相关代谢途径的抑制剂。

• 小鼠异种移植模型： 建立 CDX (Cell Line-Derived Xenograft) 模型，用于评估药物的体内药效。

4. 注意事项

• 细胞聚集： CHLA-15 具有较强的聚集倾向，传代消化时需小心吹打以获得单细胞悬液，否则会影响计数准确性和接种均匀度。

• 培养基变色： 复发性肿瘤细胞代谢活跃，产酸较多，需注意观察 pH 值变化并定期（每周 2-3 次）更换培养基。

English Datasheet

1. General Product Information

• Product Name: BioVector® CHLA-15 Human Neuroblastoma Cell Line

• Source: Retroperitoneal tumor (Relapsed Neuroblastoma)

• Molecular Profile:MYCN Amplification; characterized by decreased sensitivity to standard chemotherapeutic agents such as alkylators.

• Growth Properties: Adherent (tends to form multi-layered clusters).

• Morphology: Epithelial-like and small round cells with scant cytoplasm; often displays short neurite-like processes.

2. Culture Conditions

• Basal Medium: BioVector® IMDM or DMEM/F-12 (1:1).

• Serum Supplement: 10% - 20% BioVector® Fetal Bovine Serum (FBS).

• Supplements: Supplementation with 1x ITS (Insulin-Transferrin-Selenium) is recommended to maintain viability at low seeding densities.

• Incubation: 37°C, 5% CO2.

• Subculturing: 1:2 to 1:4 ratio; growth is relatively slow compared to some primary neuroblastoma lines.

3. Applications

• Drug Resistance Profiling: Comparing relapsed cell phenotypes against treatment-naive models to identify molecular pathways of acquired resistance.

• Targeting MYCN: Utilizing the line as a model for testing inhibitors targeting MYCN transcription, protein stability, or downstream metabolic effectors.

• In Vivo Modeling: Creating CDX (Cell Line-Derived Xenograft) models to evaluate the pharmacodynamics of novel neuroblastoma drug candidates.

4. Key Usage Notes

• Cluster Management: CHLA-15 cells naturally grow in clusters. During trypsinization, gentle but thorough trituration is required to achieve a single-cell suspension for accurate experimental setup.

• Nutrient Demand: Due to the metabolic profile of relapsed tumor cells, regular media changes (2-3 times per week) are necessary to prevent the accumulation of lactic acid and depletion of glucose.

注意 / Note: BioVector® CHLA-15 应在生物安全二级 (BSL-2) 条件下操作。鉴于该细胞系源自复发肿瘤，其表型可能在多次传代后发生微小漂移，建议定期通过 FISH 验证 MYCN 的扩增状态。BioVector® CHLA-15 should be handled under Biosafety Level 2 (BSL-2) conditions. Given its origin from a relapsed tumor, the phenotype may undergo minor drift after extensive passaging; BioVector® recommends periodically verifying MYCN amplification status via FISH.

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

电话:400-800-2947

工作QQ/微信同号:1843439339

网址

http://www.biovector.net